Key facts
- This page summarizes Catherine M. Szyman's Form 4 filing for Edwards Lifesciences Corp (EW).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 06 May 2024, 19:18.
Catherine M. Szyman - 03 May 2024 Form 4 Insider Report for Edwards Lifesciences Corp (EW)
- Reporting relationship
- CVP, Critical Care
- Issuer ticker
- EW
- Reported as of
- 03 May 2024
- Net transaction value
- -$334,174
- SEC form
- 4
- Accepted by SEC
- 06 May 2024, 19:18:20 UTC
- Prior SEC filing
- 26 Apr 2024
- Next SEC filing
- 09 May 2024
- Source filing
- View source filing
- Reporting owner signature
- Linda J. Park, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Catherine M. Szyman filed Form 4 for Edwards Lifesciences Corp (EW) on 06 May 2024.
Change
- Previous filing in this sequence was filed on 26 Apr 2024.
- Current net transaction value: -$334,174.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EW
transaction
Common Stock
Tax liability
- Transaction value
- $40,744
- Shares
- -479
- Change %
- -1.1%
- Price
- $85.06
- Shares after
- 43,222
- Date
- 03 May 2024
- Ownership
- Direct
EW
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +5,796
- Change %
- +13%
- Price
- $0.000000
- Shares after
- 49,018
- Date
- 04 May 2024
- Ownership
- Direct
- Footnotes
- F1
EW
transaction
Common Stock
Tax liability
- Transaction value
- $293,430
- Shares
- -3,442
- Change %
- -7%
- Price
- $85.25
- Shares after
- 45,576
- Date
- 04 May 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EW
transaction
Derivative
Performance Rights
Options Exercise
- Transaction value
- $0
- Shares
- -5,796
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 04 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,796
- Exercise price
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.
SEC remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.